Skip to main content
Clinical Trials/NCT05407870
NCT05407870
Completed
N/A

A Comparative Study of the Efficacy and Safety of Etomidate Compared to Propofol in Gastric Endoscopic Submucosal Dissection: a Prospective, Single-center, Randomized, Double-blind, Non-inferiority Study

Korea University Anam Hospital1 site in 1 country138 target enrollmentJune 9, 2022

Overview

Phase
N/A
Intervention
Propofol Injection
Conditions
Sedation Complication
Sponsor
Korea University Anam Hospital
Enrollment
138
Locations
1
Primary Endpoint
Respiratory adverse event
Status
Completed
Last Updated
last year

Overview

Brief Summary

During endoscopy, the patient is sedated to relieve pain and improve the ease of the procedure. Sedation endoscopy using propofol is effective, but has the disadvantage that cardiopulmonary side effects are frequently observed. However, etomidate is known to have hemodynamic and respiratory stability.The purpose of this study was to compare the efficacy and safety of etomidate and propofol in sedated gastric endoscopic submucosal dissection.

Registry
clinicaltrials.gov
Start Date
June 9, 2022
End Date
November 24, 2022
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Keum, Bo Ra

Professor

Korea University Anam Hospital

Eligibility Criteria

Inclusion Criteria

  • Age 19-80
  • American Society of Anesthesiologists Physical Status Classification System (ASA) score of I, II, III
  • Scheduled endoscopy

Exclusion Criteria

  • Pregnancy
  • Previous study History of hypersensitivity to drugs or substances containing soy or egg ingredients
  • Those who think that tracheal intubation will be difficult
  • Obstructive sleep apnea
  • History of side effects from previous sedatives
  • People with severe liver disease, kidney disease, or heart disease
  • Those who want a non-sleeping endoscope
  • A person who refuses to provide consent
  • SBP \< 80mmHg or SpO2 \< 90%
  • Patients with adrenocortical dysfunction, chronic steroid users

Arms & Interventions

Propofol

induction - 0.5mg/kg Propofol maintenance - 0.25mg/kg Propofol

Intervention: Propofol Injection

Etomidate

induction - 0.25mg/kg Propofol + 0.05mg/kg Etomidate maintenance - 0.05mg/kg Etomidate

Intervention: Etomidate Injection

Outcomes

Primary Outcomes

Respiratory adverse event

Time Frame: during gastric endoscopic submucosal dissection

the number and proportion of cases of respiratory depression

Secondary Outcomes

  • ESD clinical outcomes(From enrollment to the first clinic visit (within 60 days))
  • Adverse events and procedure interruptions(during gastric endoscopic submucosal dissection)
  • Sedation-related profile(From initial administering the sedative drug to endoscopy room discharge (up to 2 hours); dose (ml))
  • Satisfaction assessment(From initial administering the sedative drug to endoscopy room discharge; satisfaction score (0-10, 10 is the highest score))
  • Hemodynamic changes(From date of randomization until the date of first documented progression (up to 2 hours))
  • Factors associated with adverse events(From date of randomization until the date of first documented progression (up to three days))

Study Sites (1)

Loading locations...

Similar Trials